FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
Active sales and marketing efforts of GEMS™ WIN as a Windows 7 compatible ECG management software nets new license agreements from a wide array of customers
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today announced that sales of its new Global ECG Management System release (GEMS™ WIN), a Windows 7 compatible version of the Company’s GEMS™ software technology, is gaining traction. CardioComm Solutions’ release of GEMS™ WIN is in response to the recent termination of Microsoft support for Windows XP as of April 2014. The GEMS™ WIN software release allows for functional operation of GEMS™ on the Windows 7 Operating System.
The Company recently confirmed completion of an organizational refocusing of resources on GEMS™ WIN inside sales and targeting their existing customer base of GEMS™ users. “Response from our customers has been extremely encouraging. With results based on just over two months of effort since the June release of GEMS™ WIN, the Company has already secured purchase orders as part of a sales funnel currently in excess of $300,000 in annual and recurrent licensing fees,” reported Simi Grosman, member of the Company’s Board of Directors. “Equally encouraging is the fact that the business is coming from a wide range of target groups including Independent Diagnostic Testing Facilities (IDTFs), Community Hospitals, Universities and Cardiology Centres.”
CardioComm Solutions has also initiated an international advertising effort to expand awareness of the availability of the Windows 7 compatible GEMS™ WIN software solution through HospiMedica, a medical publication that reaches 30,000 key hospital decision makers and medical equipment dealers/distributors in Europe, Latin America, the Middle East/Africa and Asia/Pacific. CardioComm Solutions already boasts a client base that extends into 20 countries and the Company’s international distributors are expected to be able to leverage this publication to gain further traction within their target markets.
“The initial sales focus has been on our extensive customer base of current US and Canadian health care providers and customers,” noted Etienne Grima, CEO of CardioComm Solutions, Inc. “The easy-to-use GEMS™ XP based user interface has been maintained in the GEMS™ WIN upgrade. Providing our clients with the ability for continued normal operations with minimum downtime and no staff re-training and education during the upgrade process is a compelling proposition for our current users,” Grima added. The GEMS™ WIN system can track and store comprehensive patient information including enrollments, symptoms, medications, diagnoses, inventory, devices, follow-ups, schedules and a multitude of reporting options for a variety of patient follow-ups and tests. The GEMS™ WIN user-friendly patient management system is the easiest way to receive and store ECGs and patient information on the market today and is specifically designed to accommodate busy clinics and healthcare professionals with their daily tasks.
The Company intends to solidify its technology provider relationship with hundreds of cardiology-based clinical providers and monitoring services across Canada, the United States and internationally. CardioComm Solutions’ GEMS™ WIN release will soon offer its customers the use of new arrhythmia monitors with planned wireless capability to address currently underserved demands for a reliable and cost-effective solution, solutions that will open new sales opportunities where providing wireless devices for ambulatory arrhythmia monitoring presents a universal need.
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of